EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
.png)
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
The European Academy of Paediatrics has warned the EU to correct a new law that inadvertently prevents the provision of essential medical devices for children, citing unintended consequences of the EU Medical Devices Regulation (MDR).
In a letter sent on June 27, 2023 to EU Health Commissioner Stella Kyriakides, the Academy, along with 22 other medical associations, cited that the law that requires companies to recertify their products. Though the deadline for companies to achieve this has been extended until 2027/2028, reports from doctors claim that the new legislation has caused shortages of certain lifesaving equipment, especially those from small drug device companies that cannot afford the new compliance procedure, and that the extension has not solved the issue for these companies. All drug device companies are required by the new law to sign a contract by September 2024 with a notified body to begin the recertification process. The law came into effect in 2021 with the goal of preventing health scandals.
The group cited one particular company that received invoices from a notified body of over EUR €800,000 for a single device to be assessed. The device is already on the market for, at the most, 5 years of market access. At nearly 150 times more costly than the process in the United States for the same device, the group warns that similar situations may cause lifesaving drug devices to disappear from the market. In the letter, the associated groups urged for access protection of certain drug devices for children and patients with rare diseases. They reported that a specific type of catheter utilised in lifesaving surgery on newborns with heart defects has become unavailable due to the law, as well as shortages in dialysis machines for children with kidney disease.
The group emphasised the dire consequences of such shortages in their letter, stating “This will result in an avoidable risk of death and serious injury – not as a consequence of unsafe medical devices, but as a consequence of [the] disappearance of devices due to unforeseen effects of the EU Medical Devices Regulation.”
Source: EU must prevent medical devices for children from disappearing, say doctors groups [Accessed June 28, 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/eu-must-prevent-medical-devices-children-disappearing-say-doctors-groups-2023-06-27/
Related News
-
News Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. -
News Updated: Samsung Biologics to manufacture Pfizer's biosimilars products
Samsung Biologics agrees to use their biocampus Plant 4 for the manufacture of a line of products from Pfizer. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Soft capsule technology: modified pea starch as a vegetal origin alternative to gelatin in capsule shell
The latest soft capsule technology from Roquette using modified pea starch as an alternative to gelatin. -
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts. -
News High demand: Vetter expands production capacities and services offered at its Austrian site
Pharma service provider further expands offerings for clinical development and manufacturing -
News Novavax will provide adjuvant Matrix-M for vaccine research with 3-year partnership
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research. -
News Pfizer and Thermo Fisher Scientific partner to bring accessible NGS-based testing to international markets
The collaboration between the pharmaceutical giant and scientific technology provider will aim to bring rapid and localised services to areas around the globe that lack affordable advanced genomic testing for breast and lung cancer.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance